Check-Cap (CHEK) received approval from the FDA for the Investigational Device Exemption (IDE) application
Check-Cap issued the shareholders letter on January 5th, 2022 stating –
Dear Check-Cap Shareholders,
We have greatly appreciated your support throughout 2021, a year during which we have continued our progress as we prepare to initiate our U.S. pivotal study of C-Scan, including strengthening our manufacturing capacity, clinical affairs team and our balance sheet. As we begin 2022, I want to take the opportunity to share updates on our C-Scan program as well as provide a recap of our 2021 progress.
I will now walk you through our key updates in more detail:
U.S. Pivotal Study: In 2021, we received approval from the Food and Drug Administration (FDA) of our Investigational Device Exemption (IDE) application, permitting the Company to initiate the pivotal study in the U.S. Recently, we submitted a supplement to the FDA to amend the study design to add a first part to the trial that is designed to enable further calibration of the system, specifically for the average risk U.S. population. We expect the agency to provide its feedback during Q1 2022 and subject to agency’s approval for our amended study design, we anticipate beginning the initial part of the U.S. pivotal study in the March-April 2022 timeframe and the second part of the pivotal study in Q4 2022.
This expanded two-part pivotal study will initially focus on device calibration and enhancement of our algorithms, followed by a second portion which will compare performance of C-Scan to traditional colonoscopy, in accordance with the currently approved IDE. This second comparative portion of the study will be analyzed for statistical significance.
We plan to provide updates on the planned amended study design, as well as key milestones associated with the study progress, throughout 2022. In parallel, we continue to gather data at our Israeli sites to further calibrate the system.
Manufacturing: In 2021, Check-Cap significantly expanded C-Scan’s manufacturing capacity and its on-site production line. Taken together, these supply chain and quality infrastructure improvements are designed to ensure optimized execution of the U.S. pivotal study. The Company plans to continue investing in infrastructure enhancements to further improve its capacity and quality.
Clinical Team:In the third quarter of 2021, we strengthened our clinical team, with the appointment of Dr.Hanit Brenner-Lavieas Vice President of Clinical Affairs and additional clinical professionals. This expansion is critical to assure our preparedness for U.S. clinical operations as we roll out our pivotal study across multiple study sites. We also plan to enhance the team with additional U.S. clinical hires to allow pivotal study execution across the U.S. sites.
Breakthrough Device Designation: In early 2021, the FDA approved the Company’s Breakthrough Device Designation. We believe that this strengthens C-Scan’s recognition as an alternative method to address the significant unmet need for patient-friendly CRC screening.
CE Mark:In late 2021, the European Medical Device Regulation (MDR) issued a renewal of the Company’s CE mark approval for an additional five years. This is a regulatory achievement for the Company, among the first medical device companies to comply with the strict requirements of this new advanced directive. The updated MDR CE approval does not only permit Check-Cap to commercialize C-Scan in Europe but provides further external validation of the Company’s quality systems. While currently we remain focused primarily on the U.S. market, the renewal enables us to continue to explore opportunities to launch C-Scan in other international markets.
Cash balance: In 2021, we raised net proceeds of $31.8 million from a registered direct offering in July, in addition to $19.2 million from a warrant exercise in the first quarter, which strengthened our financial position. As of September 30, 2021, our cash and cash equivalents, restricted cash and short-term bank deposits were $56.8 million. We continue to expect this cash to fund operations well into 2023.
Patents: In 2021, we were granted four new patents:
- “Position Estimation of Imaging Capsule in Gastrointestinal Tract” granted in the U.S, covering C-Scan’s proprietary tracking technology, which enables real time tracking of the capsule and its activation when it moves throughout the colon. This functionality allows for optimal scanning along the gastrointestinal (GI) tract while maintaining low energy consumption during the procedure. The patent also covers the capsule positioning data recording utilized by the C-Scan analysis suite, which enables gastroenterologists to make a clinical decision and generate a report with their diagnosis and recommendations. Corresponding patents were issued in Japan and China and patents were approved for granting in Europe and Israel.
- “Image reconstruction with radioactive imaging” was granted in Israel, covering aspects of the technology developed by Check-Cap to perform image reconstruction of the data acquired by the C-Scan imaging capsule. This unique iterative algorithm is optimal for image reconstruction of X-ray fluorescence combined with Compton scattering for intra lumen colon imaging. Corresponding patents were also granted in the U.S, in Europe and China.
- “Nano particle detection with X-ray capsule” was granted in Europe, which covers aspects of a synergic technology for C-Scan, using gold nanoparticles attached to cancer avid antibodies that can allow selective detection of colon cancer tissue within the colon. This future technology developed by us has the potential to allow C-Scan to discriminately detect and localize cancer lesions in real time as well as potentially detect rare flat lesions that currently go mostly undetected with other screening technologies. A corresponding patent was also granted in the U.S.
- “Imaging capsule location detection” was granted in the U.S, which covers aspects of the technology developed by Check-Cap to positively identify entrance of the C-Scan capsule to the colon with high accuracy. A corresponding patent was also granted in Europe.
With these patents we have accumulated 54 granted patents and one allowed patent in main world markets, covering various aspects of our technology. In addition, we have 14 additional pending patents applications in the pipeline.
NASDAQ Listing Compliance: On December 23, 2021, we were notified by Nasdaq that we were not in compliance with the minimum bid price requirement for continued listing, which requires listed securities to maintain a minimum bid price of $1.00 per share. We have until June 21, 2022 to regain compliance with the minimum bid price requirement. In the event that we do not regain compliance after the initial 180-day period, we may then be eligible for an additional six-month extension if we meet certain listing requirements.
Looking Forward to 2022: We have had a productive year preparing our operations and clinical teams for our U.S. pivotal study and strengthening our balance sheet. Our near-term focus in the first quarter of 2022 is to obtain FDA approval of our amended pivotal study design and kick off our U.S. pivotal study following this approval.
Colorectal cancer screening rates remain low globally, especially due to the invasiveness of the colonoscopy procedure, with only abouttwo in three adults among the targeted screening population conducting a colonoscopy in the U.S. Adherence in other regions of the world, such as Europe and Asia, is even lower,. Low invasiveness tests, such as fecal occult blood tests (FOBT), exist and are included in multiple colorectal screening guidelines across countries. Other non-invasive tests such as liquid biopsy are in development. Yet, all these tests are primarily designed to detect cancer and demonstrate low sensitivity in detecting pre-cancerous polyps. As such, they do not necessarily provide patients with the time window to pre-empt the disease. We believe there is a large unmet need for apatient-friendly colorectal cancer screening option, such as C-Scan,that can overcome barriers to colonoscopy screening while also enabling detection of polyps before they turn into cancer, versus detecting cancer once it has already appeared. We look forward to continuing to make clinical progress in 2022 and potentially making C-Scan available to the U.S. population as soon as possible.
We would like to thank our dedicated employees who work tirelessly to advance C-Scan, and you, our shareholders, for your continued partnership. We appreciate your support and aim to provide multiple progress updates throughout 2022.
Chief Executive Officer